8 News & Press Releases found
Nymox Pharmaceutical Corporation News
-
NYMOX Appeals Deficiency Letter
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) reports that on January 4, 2023 the Company received a deficiency letter from The Nasdaq Stock Market (“Nasdaq”) stating that, because the Company’s common ...
-
NYMOX Announces New Marketing Submission for NYMOZARFEX for BPH
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce today that a new formal submission has been made by the Company in Europe for Fexapotide Triflutate for the treatment of benign prostatic hyperplasia ...
-
May 2023 Market Cap Requirement Update
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) reports that on November 18, 2022 the Company received a deficiency letter from NASDAQ stating the Listing Rules require listed securities to maintain and minimum market ...
-
NYMOX Provides Current Update
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current update on business developments. The Company has corresponded with and has met with the FDA during the past few months. The agency has provided very helpful feedback to ...
-
NYMOX Receives Deficiency Letter from NASDAQ
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reports that on July 7, 2022 the Company received a deficiency letter from NASDAQ stating that the Company is no longer in compliance with Nasdaq Listing Rule 5550(a)(2). The Nasdaq letter states that ...
-
NYMOX Receives RTF letter from FDA
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) Nymox reports today that it has received a Refusal to File (“RTF”) letter from FDA on Friday May 20th at 2:48 pm EST, with regard to the Company`s New Drug Application (“NDA”) ...
-
Nymox Announces $5 Million Registered Direct Offering
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced it has entered into definitive agreements with institutional and accredited investors for the purchase and sale of 3,030,304 common shares at a purchase price of $1.65 per share in a ...
-
NYMOX Announces Submission of New Drug Application (NDA) to the FDA for Fexapotide Triflutate
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce today that it has submitted the Company’s New Drug Application (NDA) to the FDA for Fexapotide Triflutate to seek marketing approval in the U.S. ...